Ocular Therapeutix outlines Q4 2026 AXPAXLI NDA plan with $530.6M cash runway into 2028
We haven't written up this one. Seeking Alpha News has the full story — the link below goes straight to it.
More in Finance & Markets
Botswana De Beers Major Shareholder In Global Diamond Consortium Deal
Botswana’s stake to increase from 15% to 30% in an expected deal with the Global Diamond Consortium of jewelry industry players.
New Oriental Education: 3 Key Takeaways for Long-Term Investors
Key PointsNet revenue grew 23.1% year over year to $1.87 billion.
Ozempic, Zepbound and other GLP-1 drugs have a possible risk of vision loss
Several medical studies have found that people taking GLP-1 medications have an elevated risk for nonarteritic anterior ischemic optic neuropathy, or NAION.
Ozempic, Zepbound and other GLP-1 drugs have a possible risk of vision loss
Several medical studies have found that people taking GLP-1 medications have an elevated risk for nonarteritic anterior ischemic optic neuropathy, or NAION.
How the world became too reliant on Jensen Huang
The chief executive’s travails are a reminder that a single point of failure is never a good thing for a big company